Why "normal" differs from lab to lab
p-Tau217 is a form of the tau protein, phosphorylated at position 217, that rises in the blood when amyloid plaques build up in the brain. Many p-tau217 assays exist, and they use different antibodies, platforms and units (pg/mL for some, a percentage or a ratio for others). Many reports use two cutoffs instead of one. A result below the lower cutoff points to amyloid being unlikely, a result above the upper cutoff points to likely, and a result in between is "intermediate" and needs follow-up.
That design works. In one study of three cohorts (786 people), a commercially available p-tau217 immunoassay identified abnormal amyloid with an area under the curve of 0.92 to 0.96. Using a three-range reference reduced the need for confirmatory testing by about 80% (Ashton, 2024). In a Swedish study of 1,213 people with cognitive symptoms, a blood test combining p-tau217 with the amyloid ratio reached an area under the curve of 0.96 to 0.97 for Alzheimer's pathology (Palmqvist, 2024).
Who the test is for
The Swedish study tested people with memory or thinking symptoms, in primary and secondary care. The three-cohort study included people with and without cognitive impairment. Advice for using the test in the clinic is narrower. The Alzheimer's Association guideline recommends blood biomarker tests only as part of a full diagnostic workup for people with cognitive impairment seen by specialists. It says tests with at least 90% sensitivity and 75% specificity can be used to triage, and tests with at least 90% sensitivity and specificity can replace amyloid PET or spinal fluid testing in that setting. It warns that many commercial tests do not meet these thresholds, especially with a single cutoff (Palmqvist, 2025).
In the US, the FDA cleared the first blood test to aid diagnosis in May 2025: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, for adults aged 55 and older with signs and symptoms of Alzheimer's disease (FDA, 2025).
If you have no symptoms, a positive p-tau217 result is harder to interpret. These tests were not validated as screening for healthy people, and the guideline does not cover that use. Ask the ordering clinician what the result would change.
What it means for an APOE4 carrier
Carrying APOE4 raises the chance of amyloid building up earlier, but it does not change how the test is read. Phoenix does not publish an APOE4-specific p-tau217 target, because none has been validated. Carriers use p-tau217 for two things:
- A baseline and a trend. Same lab, same assay, repeated over time, shows whether your own number moves.
- A conversation starter. An abnormal result is a reason to see a memory specialist, not a diagnosis.
Questions to ask your doctor
- Which assay produced this number, and what are its cutoffs?
- Is mine low, intermediate or high on that assay?
- Was this test validated for someone with my symptoms, or lack of them?
- Would you confirm with a second test, an amyloid PET scan or spinal fluid?
- Should I repeat it on the same assay, and when?
Phoenix brain biomarkers guide · Check your own blood numbers · Apply to join Phoenix (60-day money-back guarantee)